Medical/Pharmaceuticals
Lynk Pharmaceuticals Announces FDA IND Approval of Its Allosteric TYK2 Inhibitor LNK01006
HANGZHOU, China and SHANGHAI and BOSTON, Dec. 2, 2025 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on developing innovative therapies for immune and inflammatory diseases, today ann...
2025-12-02 08:00
824
Ziwig Endotest®: Scientific Validation Published in NEJM Evidence
LYON, France, Dec. 2, 2025 /PRNewswire/ -- NEJM Evidence, a journal of the New England Journal of Medicine Group, has published an article titled "Validation of a Saliva microRNA Signature for Endometriosis," dedicated to the saliva-based diagnostic test developed by Ziwig. The publication repor...
2025-12-02 06:00
766
CQ Medical® Expands Radiation Therapy Portfolio With Bionix Business Unit Acquisition
AVONDALE, Pa., Dec. 2, 2025 /PRNewswire/ -- CQ Medical, the global leader in patient radiotherapy positioning and healthcare innovation, is proud to announce the acquisition of Bionix's Radiation Therapy business unit, marking an expansion of its patient positioning and marking product portfolio....
2025-12-02 02:07
719
Generate:Biomedicines to Initiate Global Phase 3 Studies of GB-0895, a Long-Acting Anti-TSLP Antibody for Severe Asthma Engineered with AI
SOLAIRIA-1 and SOLAIRIA-2 will evaluate GB-0895 in approximately 1,600 patients with severe asthma whose disease remains inadequately controlled on current therapies These are the first global Phase 3 studies of a long-acting anti-TSLP antibody, marking a pivotal step as GB-0895 advances the pro...
2025-12-01 19:00
938
Lee's Pharm Supports Disaster Relief Efforts for Wang Fuk Court in Tai Po
HONG KONG, Dec. 1, 2025 /PRNewswire/ -- Lee's Pharmaceutical Holdings Limited (" Lee's Pharm" or the "Group", stock code: 0950.HK) expresses its deep condolences to the victims of the serious fire at Wang Fuk Court inTai Po, which caused multiple casualties and left many residents homeless and in ...
2025-12-01 18:46
953
Hedia appoints new CEO: Rasmus Kofoed to succeed Lars Christian Lund
COPENHAGEN, Denmark, Dec. 1, 2025 /PRNewswire/ -- Danish diabetes‑tech company Hedia is implementing a leadership change effective1 December 2025, when Rasmus Kofoed will take over as Chief Executive Officer (CEO). He succeeds Lars Christian Lund, who after approximately 2 years in the role has d...
2025-12-01 16:00
909
The Wisdom Derived from the Great Migration: Hakka Medicine - The Unique "Medical Epic" of the Hakka People
HONG KONG, Dec. 1, 2025 /PRNewswire/ -- From November 23rd to 25th, the 7th World Hakka Conference was held in Meizhou,Guangdong. With the theme "Gathering Global Hakka Businesspeople to Foster High-Quality Development," the conference adhered to the principles of "openness, innovation, cooperati...
2025-12-01 15:26
910
Oxford Instruments launches Imaris 11: boosting research productivity with clear, workflow-driven image analysis
LONDON, Dec. 1, 2025 /PRNewswire/ -- Oxford Instruments announces the release of Imaris 11, the latest generation of its industry-leading 3D/4D microscopy image visualisation and analysis software. The new version introduces an intuitive Workflow system, enhanced batch processing, and advanced to...
2025-12-01 09:00
1184
MetaOptics Announces Strategic Share Placement to Accelerate Growth and Meet Rising Global Demand
SINGAPORE, Dec. 1, 2025 /PRNewswire/ -- MetaOptics Ltd (Catalist: 9MT) (" MetaOptics" or the "Company", and together with its subsidiaries, the "Group"), a leading-edge semiconductor optics company, announced that it is proposing to raiseS$4.85 million through a placement of 6,685,028 new ordinary...
2025-12-01 08:30
1894
The Science of Longevity: Inside Prof. Mike Chan's Vision for Living Stronger, Smarter, and Longer
BANGKOK, Dec. 1, 2025 /PRNewswire/ -- Malaysia had a rare moment of reflection
this year when former Prime Minister Tun Dr. Mahathir Mohamad turned 100. His
milestone sparked public conversations about aging, vitality, and what it truly
means to remain strong at any age.
2025-12-01 00:57
1620
The Bioregenerative Sports Revolution: How Prof. Mike Chan Is Changing Athlete Recovery -- From Sabah to the Super Bowl
KOTA KINABALU, Malaysia, Dec. 1, 2025 /PRNewswire/ -- Big changes often start
in small ways. For Sabah FC, a top Malaysian football club, it began with a
simple agreement — a partnership with European Wellness, a medical group best
known for anti-aging and precursor stem cell therapy.
2025-12-01 00:27
1661
Perlis Royalty Join Prof. Mike Chan in Strengthening Malaysia's Fight Against Autism
KUALA LUMPUR, Malaysia, Nov. 30, 2025 /PRNewswire/ -- Malaysia's drive to modernize autism care received strong support today when the Raja Muda of Perlis, Tuanku Syed Faizuddin Putra Jamalullail, and his consort, Tuanku Dr. Hajah Lailatul Shahreen Akashah Khalil, attended the International Congr...
2025-12-01 00:07
1565
Ascletis Selects Its First Oral GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
- Utilizing Ascletis' Peptide Oral Transport ENhancement Technology (POTENT), ASC37 oral tablets achieved average absolute oral bioavailability of 4.2%, approximately 9-, 30-, and 60-fold higher than semaglutide, tirzepatide, and retatrutide in the oral SNAC formulation, respectively, in head-to...
2025-11-30 18:15
1304
Inaticabtagene Autoleucel (YORWIDATM) New Drug Application for Lymphoma Approved, China's innovative CAR-T Enters a New Era of Dual Indications
BEIJING, Nov. 28, 2025 /PRNewswire/ -- On November 28, 2025, Juventas Cell Therapy Co., Ltd. (hereinafter referred to as "Juventas") announced that its independently developed CAR-T cell therapy product, Inaticabtagene Autoleucel ( Ina-cel) (tradename: YORWIDATM), has received new drug marketing a...
2025-11-28 20:52
1074
K-Beauty & K-MediTech Expo Malaysia 2025 Concludes Successfully, Strengthening Korea-Malaysia Collaboration Across Beauty and Healthcare Sectors
PENANG, Malaysia, Nov. 28, 2025 /PRNewswire/ -- K-Beauty Expo Malaysia 2025 and K-MediTech Expo Malaysia 2025, hosted by Gyeonggi Province and organised by KINTEX, have successfully concluded at the Penang Waterfront Convention Centre (PWCC) after a dynamic three-day showcase of Korea's leading b...
2025-11-28 20:11
1382
Tianlong Strengthens Transfusion Safety with Innovative Blood Screening Solutions on World AIDS Day 2025
XI'AN, China, Nov. 28, 2025 /PRNewswire/ -- On World AIDS Day 2025, Tianlong reiterates its commitment to advancing global transfusion safety by presenting its fully integrated nucleic acid blood screening solution. Combining high automation with high-sensitivity NAT reagents, the solution enable...
2025-11-28 18:33
1162
OMRON Healthcare Surpasses 50 Million Nebulizers Sold
- Easing Burden of Respiratory Diseases Worldwide since 1978 - KYOTO, Japan, Nov. 28, 2025 /PRNewswire/ -- OMRON HEALTHCARE Co., Ltd., a global leader in the field of clinically proven, innovative medical equipment for home health monitoring and treatment, announced that cumulative sales of its ...
2025-11-28 16:00
1066
The Annals of Oncology Publishes Results of Phase II Study of Sacituzumab Tirumotecan Monotherapy for Urothelial Carcinoma
CHENGDU, China, Nov. 28, 2025 /PRNewswire/ -- Recently, Clinical study results from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", HKEX: 6990)'s TROP2 ADC sacituzumab tirumotecan (sac-TMT) monotherapy for advanced or metastatic urothelial carcinoma (UC) patients has been publ...
2025-11-28 12:32
1050
Once-Monthly GLP-1 RA | Gan & Lee Pharmaceuticals Initiates Phase 3 Clinical Study (GRADUAL-3) of the First Chinese Once-Monthly GLP-1 RA for Weight Management
BEIJING, Nov. 27, 2025 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, stock code: 603087.SH) announced the initiation of GRADUAL-3, its third large-scale phase 3 clinical study of the glucagon-like peptide-1 receptor agonist (GLP-1 RA) bofanglutide (research code: GZR18) injection in adult...
2025-11-27 16:57
990
IASO Bio Announces BLA Approval of Fucaso (Equecabtagene Autoleucel) by the Hong Kong Department of Health for the Treatment of Relapsed or Refractory Multiple Myeloma
SHANGHAI and NANJING, China and PLEASANTON, Calif., Nov. 27, 2025 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a commercial-stage biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of novel cell therapies and biologics for hematologic mali...
2025-11-27 13:44
983
Week's Top Stories
Most Reposted
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly
[Picked up by 278 media titles]
2025-12-26 12:55Vietnam's Newest EDM Destination, APLUS SAIGON, Debuts With Star-Studded Soft Opening Weekends Featuring Dombresky and Argy
[Picked up by 273 media titles]
2025-12-30 20:12
ACEN completes transition to 100% renewable energy
[Picked up by 273 media titles]
2025-12-29 18:53iQIYI LAND Yangzhou to Open on February 8, Marking New Chapter in China's Immersive Entertainment Scene
[Picked up by 268 media titles]
2026-01-01 10:00
CYFIRMA's 2025 Impact Recap Showcases DeCYFIR, Preemptive External Threat Landscape Management Platform, Delivering Measurable Global Defense Against Emerging Threats
[Picked up by 263 media titles]
2025-12-29 09:00
